Using SWOG-Medicare database to evaluate long-term toxicities of cancer survivors
使用 SWOG-Medicare 数据库评估癌症幸存者的长期毒性
基本信息
- 批准号:8620619
- 负责人:
- 金额:$ 31.48万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2013
- 资助国家:美国
- 起止时间:2013-02-15 至 2017-01-31
- 项目状态:已结题
- 来源:
- 关键词:AcuteAdverse effectsAgeAndrogensAreaBreastCancer SurvivorCancer SurvivorshipCardiovascular systemCessation of lifeClinicalClinical TreatmentClinical TrialsClinical Trials Cooperative GroupClinical Trials DatabaseCommon Terminology Criteria for Adverse EventsComorbidityCurrent Procedural Terminology CodesDataDatabasesDemographic FactorsDiabetes MellitusDiagnosisDoseEligibility DeterminationEnrollmentEvaluationFinasterideGenderHealthHealth Insurance Portability and Accountability ActHealthcare Common Procedure Coding SystemHeterogeneityHospitalizationHypertensionICD-9IncidenceInstitutional Review BoardsIntravenousKidneyLate EffectsLinkLong-Term SurvivorsMalignant NeoplasmsMalignant neoplasm of prostateMedicalMedical SurveillanceMedicareMedicare claimMethodologyNeurologicNon-Small-Cell Lung CarcinomaObservational StudyOncology GroupOralOutcomePatientsPelvic CancerPharmaceutical PreparationsPlacebosPlatinum CompoundsPopulationPreventionPrognostic FactorProstateRaceRadiationRadiation therapyRandomizedRandomized Clinical TrialsRecurrenceResearchResearch PersonnelResourcesRiskSamplingSelection BiasSouthwest Oncology GroupSurvivorsTaxane CompoundToxic effectTreatment Factoradministrative databasebasecancer recurrencecancer therapychemotherapycostdemographicsdeprivationfollow-upgastrointestinalhigh risk menimprovedmalignant breast neoplasmnovel strategiespopulation basedprognosticprospectiveprostate cancer preventionsubcutaneoustaxanetooltreatment durationtreatment effecttumor
项目摘要
DESCRIPTION (provided by applicant): There are over 12 million cancer survivors in the UC. Cancer survivorship and understanding late effects of cancer therapy is a high priority area. The linkage of the powerful SWOG clinical trial database to Medicare claims data provides a unique opportunity to evaluate late effects of therapy, and may establish a mechanism for identifying differences in outcomes between treatment groups after the clinical trial follow-up ends. We propose to use a database that has linked patients enrolled on SWOG clinical treatment and prevention trials where detailed information on demographics, tumor details, prognostic factors, clinical factors, treatment type (intravenous, subcutaneous and oral) and dose received, short term toxicities during the treatment period, recurrence and survival outcomes are captured with Medicare claims data (based on ICD-9, HCPCS, and CPT codes) which can provide long-term follow-up with underlying illnesses, comorbid conditions, new diagnoses, subsequent treatment, hospitalizations and costs/resource utilization associated with treatment. For the specific aims of
our proposal, we will use the SWOG-Medicare linked database to determine the long term cardiovascular, hematologic, gastrointestinal, renal, endocrinologic and neurologic complications of (a) patients with prostate cancer randomized to continuous vs intermittent androgen deprivation (b) patients with prostate cancer treated with and without androgen deprivation (c) patients with breast and prostate cancer treated with and without taxanes (d) patients with non-small cell lung cancer treated with and without platinum agents (e) patients with pelvic cancer treated with chemotherapy and radiation vs. radiation alone. For each of these sub-aims, we will examine how these complications vary by pre-existing co-morbidities, such as diabetes and hypertension, as well as clinical and demographic factors, and examine the relationship between short term toxicities assessed during therapy on a clinical trial, as characterized by the Common Toxicity Criteria (CTC-AE), and long-term toxicities. Using the unique and valuable linked Medicare claims database with the NCI clinical trials database of the Southwest Oncology Group, we can perform analyses that overcome limitations of previously conduced population based research that utilized the SEER-Medicare database alone. If we can better predict who is at greatest risk for late toxicity, and who is not, we can improve long term outcomes for the growing population of cancer survivors
描述(由申请人提供):UC中有超过1200万癌症幸存者。癌症存活率和了解癌症治疗的晚期效应是一个高度优先的领域。强大的SWOG临床试验数据库与医疗保险索赔数据的链接提供了评估治疗后期效果的独特机会,并可能建立一种机制,用于在临床试验随访结束后识别治疗组之间结果的差异。我们建议使用一个数据库,该数据库将参加SWOG临床治疗和预防试验的患者联系起来,其中包含人口统计学、肿瘤详情、预后因素、临床因素、治疗类型等详细信息(静脉、皮下和口服)和接受的剂量、治疗期间的短期毒性、复发和生存结局与Medicare索赔数据一起收集(基于ICD-9、HCPCS和CPT代码),可以提供与基础疾病、共病、新诊断、后续治疗、住院和与治疗相关的成本/资源利用的长期随访。具体目标是
我们的建议,我们将使用SWOG-Medicare链接数据库来确定长期心血管,血液,胃肠道,肾脏,内分泌和神经系统并发症:(a)前列腺癌患者随机分配至连续与间歇雄激素剥夺组(B)前列腺癌患者接受和不接受雄激素剥夺治疗(c)乳腺癌和前列腺癌患者接受和不接受紫杉烷类治疗(d)用和不用铂剂治疗的非小细胞肺癌患者(e)用化疗和放射治疗的骨盆癌患者与单独放射治疗的骨盆癌患者。对于这些子目标中的每一个,我们将检查这些并发症如何因预先存在的合并症(如糖尿病和高血压)以及临床和人口统计学因素而变化,并检查临床试验治疗期间评估的短期毒性(以通用毒性标准(CTC-AE)为特征)与长期毒性之间的关系。使用独特而有价值的关联医疗保险索赔数据库与西南肿瘤组的NCI临床试验数据库,我们可以进行分析,克服以前单独使用SEER-医疗保险数据库进行的基于人群的研究的局限性。如果我们能更好地预测谁是晚期毒性的最大风险,谁不是,我们就能改善不断增长的癌症幸存者的长期预后。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
DAWN HERSHMAN其他文献
DAWN HERSHMAN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('DAWN HERSHMAN', 18)}}的其他基金
Efficacy of a Pill-Dispensing System to Increase Disposal of Unused Opioids and Reduce Refill Rates after Cancer Surgery
药丸分配系统在增加未使用阿片类药物的处置并降低癌症手术后补充率方面的功效
- 批准号:
10665967 - 财政年份:2023
- 资助金额:
$ 31.48万 - 项目类别:
Intervention to iMProve AdherenCe equiTably (IMPACT TRIAL)
公平地提高依从性的干预(影响试验)
- 批准号:
10657754 - 财政年份:2021
- 资助金额:
$ 31.48万 - 项目类别:
Intervention to iMProve AdherenCe equiTably (IMPACT TRIAL)
公平地提高依从性的干预(影响试验)
- 批准号:
10437181 - 财政年份:2021
- 资助金额:
$ 31.48万 - 项目类别:
Intervention to iMProve AdherenCe equiTably (IMPACT TRIAL)
公平地提高依从性的干预(影响试验)
- 批准号:
10494225 - 财政年份:2021
- 资助金额:
$ 31.48万 - 项目类别:
Delays in Acquisition of Oral Antineoplastic Agents
口服抗肿瘤药物的获取延迟
- 批准号:
9975367 - 财政年份:2020
- 资助金额:
$ 31.48万 - 项目类别:
A randomized trial of topical menthol for chemotherapy induced neuropathy
局部薄荷醇治疗化疗引起的神经病变的随机试验
- 批准号:
8759581 - 财政年份:2014
- 资助金额:
$ 31.48万 - 项目类别:
Using SWOG-Medicare database to evaluate long-term toxicities of cancer survivors
使用 SWOG-Medicare 数据库评估癌症幸存者的长期毒性
- 批准号:
8997455 - 财政年份:2013
- 资助金额:
$ 31.48万 - 项目类别:
相似海外基金
Unraveling Adverse Effects of Checkpoint Inhibitors Using iPSC-derived Cardiac Organoids
使用 iPSC 衍生的心脏类器官揭示检查点抑制剂的副作用
- 批准号:
10591918 - 财政年份:2023
- 资助金额:
$ 31.48万 - 项目类别:
Optimization of mRNA-LNP vaccine for attenuating adverse effects and analysis of mechanism behind adverse effects
mRNA-LNP疫苗减轻不良反应的优化及不良反应机制分析
- 批准号:
23K15383 - 财政年份:2023
- 资助金额:
$ 31.48万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of adverse effects of combined exposure to low-dose chemicals in the living environment on allergic diseases and attempts to reduce allergy
阐明生活环境中低剂量化学品联合暴露对过敏性疾病的不良影响并尝试减少过敏
- 批准号:
23H03556 - 财政年份:2023
- 资助金额:
$ 31.48万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Green tea-based nano-enhancer as an adjuvant for amplified efficacy and reduced adverse effects in anti-angiogenic drug treatments
基于绿茶的纳米增强剂作为抗血管生成药物治疗中增强疗效并减少不良反应的佐剂
- 批准号:
23K17212 - 财政年份:2023
- 资助金额:
$ 31.48万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Effects of Tobacco Heating System on the male reproductive function and towards to the reduce of the adverse effects.
烟草加热系统对男性生殖功能的影响以及减少不利影响。
- 批准号:
22H03519 - 财政年份:2022
- 资助金额:
$ 31.48万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Mitigating the Adverse Effects of Ultrafines in Pressure Filtration of Oil Sands Tailings
减轻油砂尾矿压力过滤中超细粉的不利影响
- 批准号:
563657-2021 - 财政年份:2022
- 资助金额:
$ 31.48万 - 项目类别:
Alliance Grants
1/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
1/4-破译ECT结果和不良反应的机制(DECODE)
- 批准号:
10521849 - 财政年份:2022
- 资助金额:
$ 31.48万 - 项目类别:
4/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
4/4-破译ECT结果和不良反应的机制(DECODE)
- 批准号:
10671022 - 财政年份:2022
- 资助金额:
$ 31.48万 - 项目类别:
2/4 Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
2/4 ECT 结果和不良反应的破译机制(DECODE)
- 批准号:
10670918 - 财政年份:2022
- 资助金额:
$ 31.48万 - 项目类别:
Adverse Effects of Using Laser Diagnostics in High-Speed Compressible Flows
在高速可压缩流中使用激光诊断的不利影响
- 批准号:
RGPIN-2018-04753 - 财政年份:2022
- 资助金额:
$ 31.48万 - 项目类别:
Discovery Grants Program - Individual